This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jakubczak, J. L. Articles by Hallenbeck, P. L. Search for Related Content PubMed PubMed Citation Articles by Jakubczak, J. L. Articles by Hallenbeck, P. L.

An Oncolytic Adenovirus Selective for Retinoblastoma Tumor Suppressor Protein Pathway-defective Tumors

Dependence on E1A, the E2F-1 Promoter, and Viral Replication for Selectivity and Efficacy

Genetic Therapy, Inc., Gaithersburg, Maryland 20878

The use of oncolytic adenoviruses as a cancer therapeutic is dependent on the lytic properties of the viral life cycle, and the molecular differences between tumor cells and nontumor cells. One strategy for achieving safe and efficacious adenoviral therapies is to control expression of viral early gene(s) required for replication with tumor-selective promoter(s), particularly those active in a broad range of cancer cells. The retinoblastoma tumor suppressor protein (Rb) pathway is dysregulated in a majority of human cancers. The human E2F-1 promoter has been shown to be selectively activated/derepressed in tumor cells with a defect in the Rb pathway. Ar6pAE2fE3F and Ar6pAE2fF are oncolytic adenoviral vectors (with and without the viral E3 region, respectively) that use the tumor-selective E2F-1 promoter to limit expression of the viral E1A transcription unit, and, thus, replication, to tumor cells. We demonstrate that the antitumor activity of Ar6pAE2fF in vitro and in vivo is dependent on the E2F-1 promoter driving E1A expression in Rb pathway-defective cells, and furthermore, that its oncolytic activity is enhanced by viral replication. Selective oncolysis by Ar6pAE2fF was dependent on the presence of functional E2F binding sites in the E2F-1 promoter, thus linking antitumor viral activity to the Rb pathway. Potent antitumor efficacy was demonstrated with Ar6pAE2fF and Ar6pAE2fE3F in a xenograft model following intratumoral administration. Ar6pAE2fF and Ar6pAE2fE3F were compared with Addl1520, which is reported to be molecularly identical to an E1B-55K deleted vector currently in clinical trials. These vectors were compared in in vitro cytotoxicity and virus production assays, after systemic delivery in an in vivo E1A-related hepatotoxicity model, and in a mouse xenograft tumor model after intratumoral administration. Our results support the use of oncolytic adenoviruses using tumor-selective promoter(s) that are activated or derepressed in tumor cells by virtue of a particular defective pathway, such as the Rb pathway.

This article has been cited by other articles:

				E. V. Shashkova, K. Doronin, J. S. Senac, and M. A. Barry Macrophage Depletion Combined with Anticoagulant Therapy Increases Therapeutic Window of Systemic Treatment with Oncolytic Adenovirus Cancer Res., July 15, 2008; 68(14): 5896 - 5904. [Abstract] [Full Text] [PDF]

				S. Ganesh, M. Gonzalez-Edick, D. Gibbons, M. Van Roey, and K. Jooss Intratumoral Coadministration of Hyaluronidase Enzyme and Oncolytic Adenoviruses Enhances Virus Potency in Metastatic Tumor Models Clin. Cancer Res., June 15, 2008; 14(12): 3933 - 3941. [Abstract] [Full Text] [PDF]

				M. M. Alonso, M. Cascallo, C. Gomez-Manzano, H. Jiang, B. N. Bekele, A. Perez-Gimenez, F. F. Lang, Y. Piao, R. Alemany, and J. Fueyo ICOVIR-5 Shows E2F1 Addiction and Potent Antiglioma Effect In vivo Cancer Res., September 1, 2007; 67(17): 8255 - 8263. [Abstract] [Full Text] [PDF]

				S. Ganesh, M. Gonzalez Edick, N. Idamakanti, M. Abramova, M. VanRoey, M. Robinson, C.-O. Yun, and K. Jooss Relaxin-Expressing, Fiber Chimeric Oncolytic Adenovirus Prolongs Survival of Tumor-Bearing Mice Cancer Res., May 1, 2007; 67(9): 4399 - 4407. [Abstract] [Full Text] [PDF]

				P. S. Reddy, S. Ganesh, and D.-C. Yu Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clin. Cancer Res., May 1, 2006; 12(9): 2869 - 2878. [Abstract] [Full Text] [PDF]

				N. Ramesh, Y. Ge, D. L. Ennist, M. Zhu, M. Mina, S. Ganesh, P. S. Reddy, and D.-C. Yu CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor-Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer Clin. Cancer Res., January 1, 2006; 12(1): 305 - 313. [Abstract] [Full Text] [PDF]

				Y. Li, N. Idamakanti, T. Arroyo, S. Thorne, T. Reid, S. Nichols, M. VanRoey, G. Colbern, N. Nguyen, O. Tam, et al. Dual Promoter-Controlled Oncolytic Adenovirus CG5757 Has Strong Tumor Selectivity and Significant Antitumor Efficacy in Preclinical Models Clin. Cancer Res., December 15, 2005; 11(24): 8845 - 8855. [Abstract] [Full Text] [PDF]

				S. Ghosh and G. J. Duigou Decreased Replication Ability of E1-Deleted Adenoviruses Correlates with Increased Brain Tumor Malignancy Cancer Res., October 1, 2005; 65(19): 8936 - 8943. [Abstract] [Full Text] [PDF]

				M. Zhu, J. A. Bristol, Y. Xie, M. Mina, H. Ji, S. Forry-Schaudies, and D. L. Ennist Linked Tumor-Selective Virus Replication and Transgene Expression from E3-Containing Oncolytic Adenoviruses J. Virol., May 1, 2005; 79(9): 5455 - 5465. [Abstract] [Full Text] [PDF]

				Y. Wang, S.-A. Xue, G. Hallden, J. Francis, M. Yuan, B. E. Griffin, and N. R. Lemoine Virus-Associated RNA I-Deleted Adenovirus, a Potential Oncolytic Agent Targeting EBV-Associated Tumors Cancer Res., February 15, 2005; 65(4): 1523 - 1531. [Abstract] [Full Text] [PDF]

				D. T. Rein, M. Breidenbach, T. O. Kirby, T. Han, G. P. Siegal, G. J. Bauerschmitz, M. Wang, D. M. Nettelbeck, Y. Tsuruta, M. Yamamoto, et al. A Fiber-Modified, Secretory Leukoprotease Inhibitor Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer Clin. Cancer Res., February 1, 2005; 11(3): 1327 - 1335. [Abstract] [Full Text] [PDF]

				C.-T. Lee, K.-H. Park, K. Yanagisawa, Y. Adachi, J. E. Ohm, S. Nadaf, M. M. Dikov, D. T. Curiel, and D. P. Carbone Combination Therapy with Conditionally Replicating Adenovirus and Replication Defective Adenovirus Cancer Res., September 15, 2004; 64(18): 6660 - 6665. [Abstract] [Full Text] [PDF]

				R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312. [Abstract] [Full Text] [PDF]

				J. Li, C. M. Weghorst, M. Tsutsumi, M. J. Poi, T. J. Knobloch, B. C. Casto, W. S. Melvin, M.-D. Tsai, and P. Muscarella Frequent p16INK4A/CDKN2A alterations in chemically induced Syrian golden hamster pancreatic tumors Carcinogenesis, February 1, 2004; 25(2): 263 - 268. [Abstract] [Full Text] [PDF]